Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02493023
Other study ID # 2010/3385
Secondary ID
Status Completed
Phase N/A
First received July 1, 2015
Last updated March 29, 2016
Start date October 2011
Est. completion date August 2015

Study information

Verified date March 2016
Source St. Olavs Hospital
Contact n/a
Is FDA regulated No
Health authority Norway:National Committee for Medical and Health Research Ethics
Study type Interventional

Clinical Trial Summary

Bronchoscopic diagnosis and staging of lung cancer must be gentle and quick, and requires optimal sampling precision.Electromagnetic navigation systems are promising for intraoperative guiding based on maps made of preoperative CT images. Navigation accuracy depends largely on correct alignment of preoperative images to the patient´s position in space during endoscopy. In this study, the accuracy of a new fast and automatic image-to-patient registration method during the initial phase of bronchoscopy is assessed in patients referred for lung cancer investigation.


Description:

This is an accuracy study of a new automatic CT-to-patient registration technique for bronchoscopy and endobronchial ultrasound bronchoscopy (EBUS). An in-house research and development navigation platform displays the intraoperative position of the endoscope inside the airways, and shows its exact position in three-dimensional (3D) maps made from the patients' own preoperative CT images. The navigation system is used for acquiring position data from a bronchoscope or EBUS-scope (same sort of output data acquired from both endoscopes in this study) equipped with a position sensor for electromagnetic tracking. From intraoperative position data, the accuracy of the image-to-patient registration and the navigation system accuracy can be calculated. When targeting a certain lymph node or tumor for sampling, the pulmonologist can use electromagnetic navigation combined with preoperative CT images to navigate directly, precisely and accurately to the area of interest. Functional systems for navigated bronchoscopy and EBUS may therefore lead to considerable improvements in lung cancer diagnosis and mediastinal staging.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- referred to thoracic department St Olavs Hospital due to suspicion of lung cancer

- informed consent

Exclusion Criteria:

- pregnancy

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
navigated bronchoscopy


Locations

Country Name City State
Norway Department of Thoracic Medicine, St Olavs Hospital Trondheim

Sponsors (3)

Lead Sponsor Collaborator
St. Olavs Hospital Norwegian University of Science and Technology, SINTEF Health Research

Country where clinical trial is conducted

Norway, 

References & Publications (1)

Sorger H, Hofstad EF, Amundsen T, Langø T, Leira HO. A novel platform for electromagnetic navigated ultrasound bronchoscopy (EBUS). Int J Comput Assist Radiol Surg. 2015 Nov 28. [Epub ahead of print] — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary endoscope position (measured in millimetres from origo in the x, y and z-plane) in 3 dimensional maps from preoperative CT images intraoperative positional data of bronchoscope or endobronchial ultrasound scope (EBUS) measured and stored in navigation system software, used for registration and navigation system accuracy calculations 48 hours No
Secondary duration of procedure time from first entry of endoscope through vocal cords to final withdrawal of endoscope 48 hours No
Secondary patient reported satisfaction enquiry on patients´own experience 2 hours after end of navigated bronchoscopy/EBUS procedure 48 hours No
Secondary adverse events procedure related adverse events or unexpected incidents registrated 48 hours No
See also
  Status Clinical Trial Phase
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Terminated NCT02050724 - ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT Phase 2
Suspended NCT03745859 - Evaluation of a New Open Source Virtual Bronchoscope Navigation System
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Recruiting NCT02804100 - Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients N/A
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04862780 - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2
Not yet recruiting NCT06376084 - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Recruiting NCT03402048 - The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial Phase 3
Recruiting NCT02264210 - Icotinib for Completed Resected IB NSCLC With EGFR Mutation Phase 2
Terminated NCT05153408 - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Phase 1
Completed NCT01261585 - Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT N/A
Recruiting NCT06177925 - A Phase â…ˇ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC Phase 2
Completed NCT02897778 - Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Phase 1
Completed NCT03516214 - EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations Phase 1
Completed NCT02745002 - Navigated EBUS and Functional Imaging in Lung Cancer N/A